THIRD QUARTER OF 2021 (JUL – SEP)

Net sales amounted to SEK 95.3 million (24.9), corresponding to an increase of 282 percent compared with the corresponding period in the preceding year. Simbionix is included in the amount of SEK 50.3 million.

For comparable units, sales increased by 31 percent.

Operating profit amounted to SEK 7.6 million (7.3). The outcome includes acquisition costs of SEK 21.8 million.

Net profit amounted to SEK 14.4 million (5.9), corresponding to earnings per share of SEK 0.33 (0.17).

Cash flow from operating activities amounted to SEK 51.6 million (9.2). As of September 30, 2021, cash and cash equivalents amounted to SEK 310.6 million (74.7).

On July 28, it was announced that Surgical Science had entered into an agreement to acquire Simbionix. On August 16, an Extraordinary General Meeting was held, at which the directed share issue to finance the acquisition was approved. The transfer of ownership took place on August 24, and Simbionix is consolidated from that date.

FIRST NINE MONTHS OF 2021 (JAN – SEP)

Net sales amounted to SEK 169.1 million (65.2), corresponding to an increase of 159 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 36 percent.

Operating profit amounted to SEK 12.0 million (7.3). The outcome includes acquisition costs of SEK 28.1 million.

Net profit amounted to SEK 19.4 million (5.0), corresponding to earnings per share of SEK 0.49 (0.15).

Cash flow from operating activities amounted to SEK 52.1 million (6.6).

In January, Mimic Technologies Inc., was acquired, with operations in robotic surgery. The transfer of ownership took place on January 27.

Gothenburg, Sweden, November 10, 2021
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: certifiedadviser@penser.se).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-10 08:30 CET.

Attachments

211110 Q32021 ENG

© Modular Finance, source Nordic Press Releases